Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-04-22
2008-04-22
Seaman, Margaret D. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S124000
Reexamination Certificate
active
07361667
ABSTRACT:
The present invention describes a method for the treatment of attention deficit hyperactivity disorder (ADHD), conduct disorder, alcohol addiction, tobacco addiction, nicotine addiction, parkinsonism including Parkinson's disease, female and male orgasmic disorders, female and male sexual arousal disorders, hypoactive sexual desire disorder, and disorders characterized by anxiety and/or depression. In this method, a therapeutically effective, nontoxic dose of a 4′,4″-substituted 3α-(diphenylmethoxy) tropane analog or a pharmaceutically acceptable salt thereof is administered to the patient in need of such treatment.
REFERENCES:
patent: 3452029 (1969-06-01), Childress et al.
patent: 5792775 (1998-08-01), Newman et al.
Katz, JL et al ‘Novel 3 -diphenylmethoxytropane analogs: Selective dopamine uptake inhibitors with behavioral effects distinct form those of cocaine’ CA 130:217603 (1999).
Agoston, GE et al ‘A novel potoaffinity label for the dopamine transporter based on N-substituted 3 -[bis(4′-flurophenyl)methoxy]tropane’ CA 128:162491 (1998).
Zou, MF et al ‘Novel tropane-based irreversible ligands for the dopamine transporter’ CA 136:85971 (2001).
Robarge, MJ et al ‘Design and synthesis of [(2,3-dichlorophenyl)piperain-1-yl]alylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype’ CA 135:303847 (2001).
Jai, H et al ‘QSAR study of benztropine analogs for dopamine transporter’ CA 135:282655 (2001).
Bakken, GA et al ‘Classification of multidrug-resistance reversal agents using structure-based descriptors and linear discriminant analysis’ CA 134:25113 (2000).
Katz, J.L. et al., Novel 3α-Diphenylmethoxytropane Analogs: Selective Dopamine Uptake Inhibitors with Behavioral Effects Distinct from Those of Cocaine, Journal of Pharmacology and Experimental Therapeutics (Aug. 21, 1998) pp. 203-315, vol. 288, No. 1.
Bartlik, B., Kaplan, P., & Kaplan, H. S. (1995). Psychostimulants apparently reverse sexual dysfunction secondary to selective serotonin re-uptake inhibitors.Journal of sex&marital therapy, 21(4), 264-271.
Dorrego, M. F., Canevaro, L., Kuzis, G., Sabe, L., & Starkstein, S. E. (2002). A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings.The Journal of neuropsychiatry and clinical neurosciences, 14(3), 289-295.
Federici, M., Geracitano, R., Bernardi, G., & Mercuri, N. B. (2005). Actions of methylphenidate on dopaminergic neurons of the ventral midbrain,Biological psychiatry, 57(4), 361-365.
Fleming, S., Delville, Y., & Schallert, T. (2005). An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.Behavioural brain research, 156(2), 201-213.
Janowsky, D. S. (2003). Depression and dysphoria effects on the interpersonal perception of negative and positive moods and caring relationships: effects of antidepressants, amphetamine, and methylphenidate.Current psychiatry reports, 5(6), 451-459.
Jensen, P., Hinshaw, S., Swanson, J., Greenhill, L., Connors, C., Arnold, L. et al. (2001). Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers.Journal of developmental and behavioral pediatrics : JDBP, 22(1), 60-73.
Kajs-Wyllie, M. (2002). Ritalin revisited: does it really help in neurological injury?The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses, 34(6), 303-313.
Robinson, M., Anastasio, G., Little, J., Sigmon, J. L. J., Menscer, D., Pettice, Y. et al. (1995). Ritalin for nicotine withdrawal: Nesbitt's paradox revisited.Addictive behaviors, 20(4), 481-490.
Ritalin Hydrochloride. In Physicians' Desk Reference, Sixtieth Edition (Ed. David Sifton) 2006, p. 2254-2259, Thomson PDR, Montvale, NJ USA.
COGENTIN®, Physicians' Desk Reference (2001) 1892-1893, vol. 55, Medical Economics Company, Inc., Montvale, NJ.
Eiler et al., D1dopamine receptor regulates alcohol-motivated behaviors in the bed nucleus of the stria terminalis in alcohol-preferring (P) rats, Synapse, 48:45-56 (2003).
Tupala et al., Dopamine receptors and transporters in the brain reward circuits of type 1 and 2 alcoholics measured with human whole hemisphere autoradiography, NeuroImage 19 (2003) 145-155.
Bahk et al., Dopamine D1and D2receptor mRNA up-regulation in the caudate-putamen and nucleus accumbens of rat brains by smoking, Progress in Neuro-Psychopharmacology & Biological Psychiatry 26 (2002) 1095-1104.
Geracioti, et al., Low CSF concentration of a dopamine metabolite in tobacco smokers, Am. J. Psychiatry 156:1, Jan. 1999.
Campiani, et al., Synthesis and pharmacological evaluation of potent and highly selectively D3receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2receptors, J. Med. Chem. 2003, 46, 3822-3839.
Chartoff, et al., Dopamine-dependent increases in phosphorylation of cAMP response element binding protein (CREB) during precipitated morphine withdrawal in primary cultures of rat striatum, J. Neurochem. (2003) 87, 107-118.
O'Shea and Colado, Is frequent dosing with ecstasy a risky business for dopamine-containing neurons?, Trends in Pharmacological Sciences, vol. 24, No. 6, Jun. 2003.
Earle and Stuckey, Biochemical screening in the assessment of erectile dysfunction: what tests decide future therapy?, Urology 62 (4) 727-731, 2003.
Wisor, et al., Dopaminergic role in stimulant-induced wakefulness, J. Neuroscience, Mar. 1, 2002, 21(5):17871794.
Honda, et al., Dopamine D3agonists into the substantia nigra aggravate cataplexy but do not modify sleep, NeuroReport 10, 3717-3724 (1999).
Moore, Organization of midbrain dopamine systems and the pathophysiology of Parkinson's disease, Parkinsonism and Related Disorders 9 (2003) S65-S71.
Stocchi, et al., Dual dopamine agonist treatment in Parkinson's disease, J. Neurol. (2003) 250: 822-826.
Young, et al., Dopamine transporter polymorphism associated with externalizing behavior problems in children, Am. J. of Medical Genetics (Neuropsychiatric Genetics) 114:144-149 (2002).
Seeman and Madras, Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis, Behavioural Brain Research 130 (2002) 79-83.
Solanto, Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research, Behavioural Brain Research 130 (2002) 65-71.
Swanson and Volkow, Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD, Behavioural Brain Research 130 (2002) 73-78.
Wall, et al., Infralimbic D2 receptor influences on anxiety-like behavior and active memory/attention in CD-1 mice, Progress in Neuro-Psychopharmacology & Biological Psychiatry 27 (2003) 395-410.
Laakso, et al., Personality traits and striatal dopamine synthesis capacity in healthy subjects, Am. J. Psychiatry 2003; 160:904-910.
Lawford, et al., D2 dopamine receptor gene polymorphism: paroxetine and social functioning in posttraumatic stress disorder, European Neuropsychopharmacology 13 (2003) 313-320.
Buller, et al., Systemic apomorphine alters HPA axis responses to interleukin-1βadministration but not sound stress, Psychoneuroendocrinology 28 (2003) 715-732.
Brunswick, et al., Greater availability of brain dopamine transporters in major depression shown by [99mTc]TRODAT-1 SPECT imaging, Am. J. Psychiatry 2003; 160:1836-1841.
Kondo, et al., Combination of dopamine D2receptor gene polymorphisms as a possible predictor of treatment-resistance to dopamine antagonists in schizophrenic patients, Progress in Neuro-Psychopharmacology & Biological Psychiatry 27 (2003) 921-926.
Frost Brown Todd LLC
P2D Inc.
Rahmani Niloofar
Seaman Margaret D.
LandOfFree
4′,4″-substituted 3α-(diphenylmethoxy)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4′,4″-substituted 3α-(diphenylmethoxy)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4′,4″-substituted 3α-(diphenylmethoxy)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2777473